Kyowa Kirin (4151) Corporate presentation summary

Business profile and global reach

• Positioned as a unique J-GSP, with expertise across therapeutic areas and modalities; 5,161 employees and medicines available in 50+ countries.

• FY2025 revenue ¥496.8B, with 74% from ex-Japan business; listed financial indicators include core operating profit 22.1%, ROE 7.7% and DOE 4%+ with progressive dividends.

• Focus areas span bone and mineral, hematology/hemato-oncology and rare diseases; capabilities include antibody therapeutics, gene and cell therapy, next-generation antibodies, ADCs, and AI and data science.

• As of 2024, Crysvita was sold in 52 countries/regions and Poteligeo in 60; 2024 milestones included US authorization for Lenmeldy and Orchard Therapeutics acquisition.

Vision 2030 strategy

• Story for Vision 2030 prioritizes disease science in bone and mineral, intractable hematological diseases/hemato-oncology, and rare diseases, alongside exploration of unmet medical needs and disease mechanisms.

• Strategy strengthens advanced antibody technologies and hematopoietic stem cell gene therapy, applies optimal modalities, and advances discovery methods through AI and data science.

• Value delivery combines global deployment of internally developed products with partner collaborations; assets outside focus areas are designated for strategic partnering or full licensing.

Global research organization and operating model

• R&D separated into Research and Development divisions in March 2026, each led by its own CxO, to support distinctive discovery and greater research flexibility.

• Launched in January 2025, the Global Research Organization unites research engines in Japan, the US and UK; PI-led teams, Therapeutic Area Heads, and Gene & Cell Therapy and Laboratory Management groups support agile work.

• Research works with the Global Development Organization to move programs toward development; a May 2026 hub plan would integrate Tokyo and Fuji research parks across discovery, translational research, CMC and development research.

• The exploratory research flow spans technology development and idea validation through discovery, nonclinical and clinical phases, with research sites and Takasaki supporting the progression.

• Site integration at YBP is designed to bring exploratory, translational research and CMC teams together, reducing handover time and improving development speed and success rates.